UBS has initiated coverage on Addus Homecare Corp (ADUS) with a Buy rating, marking the firm's first assessment of the company. This decision reflects UBS's analysis of Addus's investment potential, taking into account its business model and industry dynamics.
Based in Frisco, Texas, Addus Homecare engages in providing in-home personal care services, employing 6,165 full-time staff. The company operates in three segments: Personal Care, Hospice, and Home Health. The Personal Care segment assists individuals at risk of hospitalization, while the Hospice segment offers care for the terminally ill. The Home Health segment delivers medical services to those recovering from illness or hospitalization.
As of September 1, 2025, Addus Homecare's stock is priced at $112.22, with a market capitalization of $2.0 billion. The company has a trailing P/E ratio of 23.52 and an earnings per share (EPS) of 4.67. Upcoming earnings are anticipated on August 3, 2026, with an estimated EPS of $1.72 and projected revenue of $384.7 million.
Analyst ratings, such as this new Buy designation, provide insights based on research and financial modeling. However, these assessments are built on assumptions that may not always materialize. Investors should consider a variety of factors, including company fundamentals and market conditions, when making decisions. Analyst opinions can evolve as new information becomes available, and differing perspectives on the same company are common in the industry.